TIDMEDEN
RNS Number : 6000S
Eden Research plc
10 July 2020
10 July 2020
Eden Research Plc
("Eden" or "Company")
Appointment of Global Head of Biology and Development
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on
sustainable biopesticides and plastic-free encapsulation technology
for use in crop protection, animal health and consumer products
industries , today announces the appointment of Dr. Aoife Dillon to
the role of Head of Biology.
Aoife joins Eden from Plant Health Care, a leading provider of
scientifically proven biological products for the agricultural
industry, where she has been Technical Director for the EMEAA
Region for the past three years. During her tenure, she drove the
R&D agenda across the region, influencing key stakeholders to
create confidence in the Plant Health Care brand and generate
market pull for the product portfolio. She was previously Chief
Technology Officer at Exosect Ltd, a formulations company focused
on the targeted delivery of biological and synthetic compounds used
in Agriculture, where she oversaw the granting of four key patents
for the company.
At Eden, she will undertake global responsibility for developing
the Company's product pipeline from a biology standpoint, working
closely with a growing R&D team. Her appointment follows the
opening of Eden's new laboratory, where the Company will conduct
in-house processes for developing and screening new products. Aoife
will be heavily involved in assessing the efficacy and safety of
new formulations and running commercial scale trials focused on
plant biology for the environment and sustainability. Aoife will
also work closely with Eden's commercial partners in order to
support their efforts and ultimately grow the list of authorised
uses for Eden's product portfolio.
Aoife has considerable regulatory affairs experience in plant
protection products and biostimulants, as well as experience
running coordinated crop trials internationally for over 20 years.
During her career, she has had roles at BASF, Horticultural
Development Company and Coillte and has a PhD in Integrated Pest
Management (IPM), a Diploma Project Management (PMBOK) and a Master
of Science (MSc) in Biological Crop Protection.
CEO Sean Smith commented: "We are pleased to welcome Aoife to
Eden. She brings an impressive range of senior executive experience
and the ability to engage with and influence key stakeholders in
the development and commercialisation of biocontrol products. Aoife
has a track record of driving change, as well as developing and
delivering on sustainability standards, which are at the core of
Eden's proposition. Her presence at our new laboratory facilities
will be integral as we ramp up our in-house capabilities to develop
our product pipeline."
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Cenkos Securities plc (Nominated advisor
and broker)
Giles Balleny / Cameron MacRitchie (corporate
finance)
Michael Johnson (sales) 020 7397 8900
Hawthorn Advisors (Financial PR)
Jana Tsiligiannis eden@hawthornadvisors.com
Ed Curtis
Notes:
Eden Research is an AIM quoted company that develops and
supplies breakthrough biopesticide products and natural,
plastic-free microencapsulation technologies to the global crop
protection, animal health and consumer products industries
Eden's Sustaine encapsulation technology harnesses the biocidal
efficacy of naturally occurring chemicals produced by plants
(terpenes) and can be used with both natural and synthetic
compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free,
biodegradable micro-spheres derived from yeast extract. They
produce stabilised aqueous suspensions which, are easy to mix and
apply, have phased release patterns, are safer for the environment
and the crops themselves.
The European Chemicals Agency (ECHA) has proposed an EU-wide
restriction on the placing on the market or use of
"intentionally-added" microplastic particles. The proposed
restriction includes the use of microplastics for agricultural and
horticultural purposes, including polymers utilized for
controlled-release fertilizers, encapsulated plant protection
products (PPPs), seed coatings, and biocides.
By 2025 in the EU, pesticides containing synthetic polymer
microplastics are likely to be banned and removed from the market.
The only acceptable alternative is the substitution with
biodegradable formulations. Reformulated products will need to be
evaluated and registered within the five-year transition
period.
Sustaine is one of the only viable, proven and immediately
registerable solutions to the microplastics problem in formulations
requiring encapsulation.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Sustaine provides a unique, environmentally friendly
solution to these problems and enables terpenes to be used as
effective, low-risk agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of 14m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, Mevalone, were approved as new ingredients for
use in plant protection products by the European Commission ("EC").
This represented a major milestone in the commercialisation of
Eden's technology and is a significant accomplishment for any
company. To illustrate this point, one should note that in 2013,
Eden's approvals represented 3 of only 10 new active ingredients
approved by the EC.
Mevalone is a foliar fungicide which has been authorised for
sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France,
Cyprus, Albania, Portugal and Macedonia.
Cedroz is a nematicide which has been authorised for sale in
Malta, Belgium and Mexico.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKKCBNOBKDQOK
(END) Dow Jones Newswires
July 10, 2020 02:00 ET (06:00 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024